Compare QURE & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QURE | PAHC |
|---|---|---|
| Founded | 1998 | 1946 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2007 | 2014 |
| Metric | QURE | PAHC |
|---|---|---|
| Price | $25.30 | $39.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 4 |
| Target Price | ★ $58.55 | $31.25 |
| AVG Volume (30 Days) | ★ 1.7M | 204.5K |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.23% |
| EPS Growth | N/A | ★ 288.74 |
| EPS | N/A | ★ 1.67 |
| Revenue | $15,751,000.00 | ★ $1,399,676,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | $142.93 | $3.28 |
| P/E Ratio | ★ N/A | $23.35 |
| Revenue Growth | N/A | ★ 33.72 |
| 52 Week Low | $7.76 | $16.16 |
| 52 Week High | $71.50 | $46.42 |
| Indicator | QURE | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 48.31 |
| Support Level | $21.64 | $38.29 |
| Resistance Level | $25.80 | $42.82 |
| Average True Range (ATR) | 1.74 | 1.56 |
| MACD | 0.47 | 0.11 |
| Stochastic Oscillator | 53.94 | 34.52 |
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.